Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET

BackgroundThe new anti-cancer drug imatinib mesylate inhibits the tyrosine kinase growth factor receptor, c-KIT, and has shown spectacular activity in patients with gastrointestinal stromal tumours (GISTs). ObjectiveTo assess whether fluorodeoxyglucose positron emission tomography (FDG PET) is suitable for response evaluation of this new type of tumour treatment. MethodsSixteen consecutive patients with irresectable or metastasized GIST or another c-KIT (CD117) positive mesenchymal tumour underwent FDG PET before and 1 week after the start of treatment with imatinib mesylate (Glivec®). Visual findings and standard uptake values (SUVs) were compared with the overall response to treatment, based on clinical and radiological response. ResultsPET visualized all known and some unknown tumour locations. The separation by PET after 1 week of treatment in ‘PET responders’ (11/16 patients, mean SUV reduction 65%) versus ‘PET non-responders’ (5/16 patients, mean SUV increase 16%) appeared to match almost perfectly with overall treatment response and proved correct in 14/15 patients (prediction sensitivity 93%). FDG uptake changes after 1 week of treatment were of greater magnitude than tumour volume changes on computed tomography at 8 weeks. Progression-free survival was significantly better in patients with a PET response (P=0.002). PET response predicted treatment outcome better than the radiological response. Finally, PET was helpful during follow-up, in discriminating side effects from tumour progression. ConclusionFDG PET is a valuable tool in patients with gastrointestinal stromal tumours treated with imatinib mesylate. It improves staging, accurately separates responders from non-responders in an early phase, and is helpful during follow-up.

[1]  G. Demetri.  Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. , 2001, Seminars in oncology.

[2]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[3]  P. Therasse.  Measuring the clinical response. What does it mean? , 2001, European journal of cancer.

[4]  C. J. Chen,et al.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.

[5]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[6]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[7]  G. Demetri,et al.  Clinical management of gastrointestinal stromal tumors: before and after STI-571. , 2002, Human pathology.

[8]  B. Druker,et al.  Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[10]  A. D. Van den Abbeele,et al.  Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). , 2002, European journal of cancer.

[11]  O. S. Nielsen,et al.  Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. , 2002, European journal of cancer.

[12]  J. Fletcher,et al.  Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. , 2002, Human pathology.

[13]  D. Lilien,et al.  F-18 FDG PET imaging in gastrointestinal stromal tumor. , 2003, Clinical nuclear medicine.

[14]  M. Fulham,et al.  FDG PET imaging of metastatic gastrointestinal stromal tumor. , 2003, Clinical nuclear medicine.

[15]  L. Sobin,et al.  Immunohistochemical Spectrum of GISTs at Different Sites and Their Differential Diagnosis with a Reference to CD117 (KIT) , 2000, Modern Pathology.

[16]  Sigrid Stroobants,et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.